Cormorant Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Cormorant Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.08M	Sell	250,000 -50,000	-17%	-$2.23M	0.46%	36
2025 Q4	$14M	Sell	300,000 -100,000	-25%	-$4.45M	0.65%	28
2025 Q3	$16.7M	Hold	400,000	–	–	1.15%	22
2025 Q2	$11.5M	Sell	400,000 -200,000	-33%	-$6.18M	0.86%	25
2025 Q1	$20.1M	Sell	600,000 -400,000	-40%	-$14.9M	1.51%	21
2024 Q4	$51.1M	Sell	1,000,000 -100,000	-9%	-$5.59M	2.81%	9
2024 Q3	$56.2M	Sell	1,100,000 -250,000	-19%	-$12.9M	2.98%	8
2024 Q2	$60.5M	Buy	1,350,000 +200,000	+17%	+$9.24M	3.49%	8
2024 Q1	$53.8M	Hold	1,150,000	–	–	2.36%	11
2023 Q4	$40.9M	Buy	1,150,000 +48,096	+4%	+$1.47M	1.95%	15
2023 Q3	$32.8M	Buy	+1,101,904	New	+$22.7M	1.91%	14

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cormorant Asset Management's CRNX Position: Q1 2026 in Review

Cormorant Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 17% in Q1 2026, selling an estimated $2.23M and leaving 250,000 shares worth $9.08M. The position accounts for 0.46% of the portfolio, ranked #36.

Cormorant Asset Management first reported a position in CRNX in Q3 2023 and has held it in 11 quarters since. The position peaked at $60.5M in Q2 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Cormorant Asset Management held 250,000 shares of Crinetics Pharmaceuticals worth $9.08M as of Q1 2026.
Cormorant Asset Management sold 50,000 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $2.23M.
Crinetics Pharmaceuticals made up 0.46% of Cormorant Asset Management's portfolio in Q1 2026, its #36 holding.
Cormorant Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Cormorant Asset Management's Crinetics Pharmaceuticals position peaked at $60.5M in Q2 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.